Polymorphisms in Genes of Drug Targets and Metabolism
作者： Pierre Bohanes , Heinz-Josef Lenz
DOI: 10.1007/978-1-4614-9135-4_17
关键词:
摘要: It is well known that patients do not respond uniformly to anticancer therapies nor develop identical toxicities when drug dose adjusted weight and height. Several mechanisms have been incriminated including genetic background. Polymorphisms in genes of targets metabolism, whom many shown be functional, represent attractive candidates could provide insights for divergences outcome a given treatment. They are increasingly recognized as an important field study promising tool tailored cancer patients. In comparison classic chemotherapeutic drugs having multiple distinct targets, target polymorphisms recently emerged “targeted therapies” may even more impact on able select benefiting from treatment at risk toxicities. this chapter, we will discuss the most studies evaluated importance metabolism with solid tumors their daily clinical practice.
springer.com
sci-hub.st 参考文章(185)
Huai-Rong Luo, Xue-Mei Lü, Yong-Gang Yao, Nobuyuki Horie, Keiichi Takeishi, Lynn B. Jorde, Ya-Ping Zhang, Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochemical Genetics. ,vol. 40, pp. 41- 51 ,(2002) , 10.1023/A:1014589105977
Andre Van Kuilenburg, Rutger Meinsma, Lida Zoetekouw, Albert Van Gennip, High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity Pharmacogenetics. ,vol. 12, pp. 555- 558 ,(2002) , 10.1097/00008571-200210000-00007
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
W Schwabe, D Behnke, P Häusler, A B Van Kuilenburg, K Höffken, A H Van Gennip, M Raida, Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5′-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)- related Toxicity Compared with Controls Clinical Cancer Research. ,vol. 7, pp. 2832- 2839 ,(2001)
Horst Buerger, Frank Gebhardt, Hartmut Schmidt, Burkhard Brandt, Werner Boecker, Kirsten Hutmacher, Alf Beckmann, Ralph Lelle, Ronald Simon, Length and Loss of Heterozygosity of an Intron 1 Polymorphic Sequence of egfr Is Related to Cytogenetic Alterations and Epithelial Growth Factor Receptor Expression Cancer Research. ,vol. 60, pp. 854- 857 ,(2000)
A F Sobrero, C Aschele, J R Bertino, Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. Journal of Clinical Oncology. ,vol. 15, pp. 368- 381 ,(1997) , 10.1200/JCO.1997.15.1.368
Isabelle Morin, Nelly Sabbaghian, Gerald Batist, Rima Rozen, Valerie Panet-Raymond, Victor Cohen, Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clinical Cancer Research. ,vol. 9, pp. 1611- 1615 ,(2003)
L Zoetekouw, H R Waterham, D J Richel, A B van Kuilenburg, F Baas, J Haasjes, R Meinsma, A H van Gennip, E W Muller, Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clinical Cancer Research. ,vol. 7, pp. 1149- 1153 ,(2001)
Ronnie Tung-Ping Poon, Sheung-Tat Fan, John Wong, Clinical Implications of Circulating Angiogenic Factors in Cancer Patients Journal of Clinical Oncology. ,vol. 19, pp. 1207- 1225 ,(2001) , 10.1200/JCO.2001.19.4.1207